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Background: It is suspected that excess of brain cholesterol plays a role in Alzheimer’s disease (AD).
Membrane-associated cholesterol was shown to be increased in the brain of individuals with sporadic AD and
to correlate with the severity of the disease. We hypothesized that an increase of membrane cholesterol could
trigger sporadic AD early phenotypes.
Results: We thus acutely loaded the plasma membrane of cultured neurons with cholesterol to reach the 30%
increase observed in AD brains. We found changes in gene expression profiles that are reminiscent of early AD
stages. We also observed early AD cellular phenotypes. Indeed we found enlarged and aggregated early endosomes
using confocal and electron microscopy after immunocytochemistry. In addition amyloid precursor protein vesicular
transport was inhibited in neuronal processes, as seen by live-imaging. Finally transient membrane cholesterol loading
lead to significantly increased amyloid-β42 secretion.
Conclusions: Membrane cholesterol increase in cultured neurons reproduces most early AD changes and could thus
be a relevant model for deciphering AD mechanisms and identifying new therapeutic targets.
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Neuropathological hallmarks of Alzheimer’s disease (AD)
are extracellular senile plaques, composed primarily of
amyloid peptides (Aβ), and intracellular neurofibrillary
tangles of hyperphosphorylated tau protein [1]. Aβ is
derived from sequential proteolytic processing of its
membrane precursor Amyloid Precursor Protein (APP)
by the β- and γ-secretases [2]. Although transgenic
mouse models expressing the mutations of APP and
components of the γ-secretase found in familial AD repro-
duce amyloid pathology, there are currently no animal
models mimicking sporadic AD [3].
Cholesterol is increasingly linked to AD pathology [4].
It is increased in AD brains [5,6] and we found by Time* Correspondence: marie-claude.potier@upmc.fr
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that a 30% cholesterol increase could be observed in AD
brain samples most likely in various cell types [7]. More-
over, increase in membrane-associated free cholesterol
were correlated with the severity of the disease as opposed
to intracellular cholesterol, cholesterol from the extracel-
lular space or from the senile plaques [5]. Additionally,
the ε4 allele of the APOE gene encoding apolipoprotein E,
the transporter of cholesterol in the brain, is the most
important risk factor of AD [8]. APP as well as β and γ-
secretases are residents of cholesterol-enriched membrane
microdomains termed lipid rafts [9,10]. Levels of choles-
terol control the partition of APP and its secretases in
lipid rafts [11,12] as well as APP internalization and Aβ
production [11,13]. Moreover, a binding site for choles-
terol in APP has been described [14].
Despite this substantial body of literature, it still re-
mains unclear whether sporadic AD could be initiatedl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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change in membrane cholesterol of neurons. To test
this hypothesis, we triggered an acute increase of choles-
terol at the membrane of neurons and assessed whether
cellular changes similar to those detected early in the
development of the disease could be observed. A 30%
membrane cholesterol increase was produced to mimick
what has been observed in AD brain samples. We did not
use 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)
inhibitors such as statins, since they lead to non-specific
effects via their action on isoprenoids and inflammation,
or drugs such as U1866A that lead to accumulation of
cholesterol in the lysosomal pathway [15-17]. We did not
use uptake of LDL-cholesterol complex either since they
can directly affect the endo-lysosomal pathway [18].
Instead we used methyl-beta-cyclodextrin/cholesterol
complex (MβCD-cholesterol) which can deliver chol-
esterol directly at the plasma membrane of cultured
neurons [12,19]. After cholesterol increase we analyzed
cellular phenotypes that correlate with sporadic AD
progression. Gene expression changes were reported to
correlate with AD pathology with a switch occurring at
Braak stage III, when profound modifications in amyloid
pathology take place [20]. Enlargement of the endosomal
compartment was described as one of the earliest pheno-
types of AD, present before the formation of plaques and
absent in other neurodegenerative diseases [21]. Aβ was
found to accumulate in these enlarged endosomes [22].
This phenotype occurs more frequently in individuals with
the ε4 allele of APOE, suggesting a possible link with chol-
esterol metabolism [21]. Another phenotype associated
with sporadic AD is axonal vesicular transport deficits, de-
scribed in samples from individuals affected by the disease
[23] and in AD mice models [24].
In this study, using our published experimental model
for loading the plasma membrane of neurons with chol-
esterol to reach an increase of 30%, corresponding to
levels detected in AD brain samples, we could recapitu-
late cellular phenotypes from early stages of the disease,
suggesting a direct causal link between high cholesterol
in the brain and cellular AD pathogenesis. We propose
membrane cholesterol accumulation in cultured neurons
to be a useful cellular model of AD.
Results and discussion
Gene expression changes after membrane cholesterol
increase were similar to changes observed in early stages
of AD
To assess gene expression modifications after loading the
plasma membrane with 30% more cholesterol, we per-
formed transcriptome analysis of embryonic rat cortical
neurons treated or not with 1.4 mM MβCD-cholesterol.
Typically the neuronal culture used contained less than
1% of non-neuronal cells (data not shown). RNAs werereverse-transcribed, labeled and hybridized to microarrays.
Among the initial 44000 probes on the chip, 1540 genes
were found to be significantly differentially expressed
(t test, p < 0.05). These genes are listed in Additional
file 1. Among them, 907 genes were down-regulated
and 633 were up-regulated after membrane cholesterol
loading.
To gain insight into the biological processes over-
represented, we performed Gene Ontology (GO) category
enrichment analysis (Additional file 2). The most significant
enriched GO categories were the ones linked to the choles-
terol pathway (GO: 003399: response to lipid, p = 3.36E-08;
GO: 0010033: response to organic substance, p = 1.84E-08;
GO: 0016126: sterol biosynthetic process, p = 7.86E-06).
We thus examined genes involved in cholesterol bio-
synthesis (PW0000454 in the Rat Genome Database, http://
rgd.mcw.edu/pathway/PW0000454/). Eleven of 18 genes
from this pathway were significantly down-regulated after
cholesterol increase (Table 1). Six genes (Ebp, Fdps,
Hmgcr, Lss, Nsdhl and Pvmk) were not differentially
expressed. We detected Dhcr24 in control conditions
only, suggesting that its expression is strongly down-
regulated after cholesterol treatment. These results are in
agreement with an adaptive compensation due to artificial
cholesterol increase. We also observed that Abca1 expres-
sion was significantly up-regulated, with a cholesterol to
control ratio of 2.89 (p = 0.0449, t test). Abca1 codes
for ABCA1, a key player in cholesterol efflux from the
cell [25].
We then compared the list of genes differentially
expressed after cholesterol increase with gene expression
profiles of sporadic AD brain samples from different Braak
stages [20]. Braak and Braak formalized the progression of
neurofibrillary pathology in the cerebral cortex based on
the topographical distribution of neurofibrillary tangles
and neuropil threads [26]. Raw data from Bossers et al.
[20] were normalized and analyzed by ANOVA. 4365
genes were found to have an interaction between expres-
sion level and Braak stage (p < 0.05). Among these, 308
were in common with our list of genes differentially
expressed after membrane cholesterol loading in neurons
(Additional file 3). To compare gene expression changes
after cholesterol increase and between Braak stages, we
performed a hierarchical clustering on the average expres-
sion levels of the 308 genes which were modulated in the
two studies (Figure 1).
Based on the level of expression of these 308 genes,
samples clustered according to their Braak stage. Namely,
early Braak AD stages I–III, displaying both intraneuronal
Aβ and amyloid plaques and late Braak AD stages IV–VI,
displaying extracellular amyloid plaques only, belonged to
distinct clusters (Figure 1). Samples corresponding to neu-
rons treated with cholesterol segregated with early AD
stages samples (Figure 1), suggesting that gene expression
Table 1 Effects of cholesterol increase on expression levels of genes involved in the cholesterol biosynthetic pathway
in cultured neurons
Gene acronym Gene full name Cholesterol/control expression ratio P value (t test)
Acat2 Acetyl-Coenzyme A acetyltransferase 2 0.32 0.00235
Cyp51 Cytochrome P450, family 51 0.48 0.00698
Dhcr24 24-dehydrocholesterol reductase NA NA
Dhcr7 7-dehydrocholesterol reductase 0.41 0.0278
Ebp Emopamil binding protein (sterol isomerase) 0.72 0.06112
Fdft1 Farnesyl diphosphate farnesyl transferase 1 0.38 0.03888
Fdps Farnesyl diphosphate synthase 0.42 0.11898
Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase 0.57 0.28355
Hmgcs1 3-hydroxy-3-methylglutaryl-CoA synthase 1 (soluble) 0.38 0.00355
Idi1 Isopentenyl-diphosphate delta isomerase 1 0.38 0.03937
Lbr Lamin B receptor 0.64 0.03795
Lss Lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase) 0.56 0.13084
Mvd Mevalonate (diphospho) decarboxylase 0.28 0.01896
Mvk Mevalonate kinase 0.49 0.00199
Nsdhl NAD(P) dependent steroid dehydrogenase-like 0.49 0.05092
Pmvk Phosphomevalonate kinase 1.16 0.74918
Sc5d Sterol-C5-desaturase 0.41 0.00863
Sqle Squalene epoxidase 0.39 0.018
Genes in bold were found to be significantly differentially expressed (t test, p < 0.05).
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more similar to changes observed in early rather than late
stages of AD. We identified four clusters of genes differen-
tially expressed after cholesterol increase. In clusters 1 (71
genes) and 4 (112 genes), representing more than 59% of
genes, expression was up- or down-regulated, respectively,
as in early Braak stages. We analyzed the Gene Ontology
annotation of these genes and found that most genes from
cluster 1 were involved in synaptic activity and in mito-
chondrial function (Additional file 4). Cluster 1 also in-
cluded genes involved in neuropeptide signaling pathway
and in endocytosis (Additional file 4). Most genes from
cluster 4 were involved in cell architecture, signaling and
regulation of cell cycle (Additional file 5).
Thus a restricted number of genes modulated by choles-
terol were sufficient to discriminate between early and late
Braak stages, supporting the hypothesis that increasing
membrane cholesterol induced changes that mirror early
AD phenotypes. We further investigated whether choles-
terol increase at the neuronal membrane could induce
early AD molecular and cellular phenotypes.
High membrane cholesterol increased early endosomes
size and aggregation
Since endosome enlargement has been reported as an
early phenotype of sporadic AD, we searched for genes
involved in endocytosis that are differentially expressed
after membrane cholesterol loading. One of the mainregulator of endocytosis is phosphatidylinositol 4,5-bispho-
sphate (PIP2) [27]. PIP2 breakdown was shown to increase
fission of endocytic vesicles from the plasma membrane
[28]. Moreover, PIP2 was recently shown to be linked
with cholesterol homeostasis [29]. Gene expression pro-
files suggested that cholesterol treatment increased PIP2
breakdown. Indeed the expression of two genes implicated
in PIP2 breakdown, Plcb1and Pik3r1, was up-regulated
after cholesterol treatment (Table 2). Microarrays results
were confirmed by quantitative PCR experiments (Table 2).
Plcb1 codes for 1-Phosphatidylinositol-4,5-bisphosphate
phosphodiesterase beta-1 (PLCβ1) which catalyzes the
formation of inositol 1,4,5-trisphosphate (IP3) and diacyl-
glycerol (DAG) from PIP2 [27]. Pik3r1 codes for phos-
phatidylinositol 3-kinase (PI3K) regulatory subunit alpha
(also called p85α). Class I PI3K phosphorylates PIP2, lead-
ing to the formation of phosphatidylinositol 3,4,5-tris-
phosphate (PIP3) [27]. Cholesterol loading could lead to
increased PIP2 breakdown and thus to increased fission of
endocytic vesicles from the membrane, resulting in higher
endocytosis, and in the formation of enlarged endosomes
as we have previously shown [13].
We then explored the impact of membrane cholesterol
loading on the morphology of early endosomes. After
treatment, neurons were fixed, stained with anti-EEA1
antibody and visualized by confocal microscopy (Figure 2A
and B). The number and size of endosomes were quanti-







Figure 1 Hierarchical Clustering of the 308 genes with significant expression changes after membrane cholesterol increase and during
AD progression (A). Magnification of the sample tree shows that early and late Braak stages are clearly discriminated while cholesterol
treatment segregates with early stages (B).
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soma was similar in control conditions (91 ± 5 endosomes,
n = 46 neurons in 3 independent experiments) and
after treatment with MβCD-cholesterol (94 ± 5 endo-
somes, n = 45 neurons in 3 independent experiments)
(p = 0.582, unpaired Student’s t test) (Figure 2C). The
average size of early endosomes of treated neurons wasTable 2 Effects of cholesterol increase on expression levels of
cultured neurons
Gene acronym Microarrays




Fyn 1.58 0.0206.2 ± 0.2 μm2 (4248 endosomes, collected from 13–17
neurons in 3 independent experiments), as compared
to 4.9 ± 0.1 μm2 (4172 endosomes, collected from 14–16
neurons in 3 independent experiments) for the control
neurons, corresponding to an increase in size of 28%
(p < 0.0001, Mann–Whitney test) (Figure 2D). We also
analyzed the size distribution of the endosomes andgenes involved in the endo-lysosomal pathway in
Quantitative PCR










Figure 2 Membrane cholesterol loading causes neuronal EEA1-positive early endosomes enlargement but does not impact on their
number, as assessed by confocal microscopy. (A) and (B) Representative confocal images of cortical neurons stained with an anti-EEA1
antibody in control conditions (A) or after cholesterol loading (B). (C) Mean number of endosomes per soma (ns stands for p > 0.05 in unpaired
Student’s t-test; n = 46 control neurons and 45 cholesterol-treated neurons observed in 3 independent experiments). (D) Mean endosomal size
(*** stands for p < 0.001, Mann–Whitney test, 4171 control endosomes and 4248 cholesterol-treated endosomes, collected in 3 independent
experiments). (E) Endosome size distribution of small-, medium- and large-sized endosomes, based on κ-means clustering and normalized to
control conditions.
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and large (Figure 2E). In the control condition, the
small, medium and large size classes represented 88.7,
10.4 and 0.9% of all endosomes, respectively. After
cholesterol treatment, 84.5, 14.0 and 1.5% of endosomes
were in the large, medium and large size classes, respect-
ively. The distribution of endosome sizes was significantly
shifted towards higher size after membrane cholesterol
loading (p = 2.8 e-07, χ2). We confirmed this change in the
morphology of early endosomes in synaptic-competentcortical neurons kept in culture for 14 days (DIV14) and
treated similarly with cholesterol (Additional file 6).
We used transmission electron microscopy (TEM) to
examine enlarged endosomes in more detail. Cortical neu-
rons were loaded with cholesterol, labeled using anti-
EEA1 antibody, and prepared for TEM (Figure 3). EEA1
immunoperoxidase precipitates were found surrounding
closely membrane-bound profiles of early endosomes as
previously shown [31], containing variable numbers of






Figure 3 Transmission electron microscopy reveals that membrane cholesterol increase leads to enlargement and aggregation of
EEA1-positive early endosomes containing more intraluminal vesicles (ILVs). (A-E) Representative electron micrographs of EEA1-labelled
structures in control (A and B) or cholesterol-treated (C, D and E) cortical neurons. Bar in E = 500 nm and is for all micrographs. (F) Surface of
individual EEA1-labelled endosomes (*** stands for p < 0.001 in unpaired t test with Welch’s correction, n = 244 control and 284 cholesterol-treated
endosomes). (G) Number of ILVs per EEA1-labelled endosome (*** stands for p < 0.001 in unpaired t test with Welch’s correction, n = 1060 control and
1978 cholesterol-treated ILVs). (H) Number of ILVs to endosomal surface ratio (ns stands for p > 0.05 in unpaired Student’s t test, n = 244 control and
284 cholesterol-treated endosomes).
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and also by some larger ones (Figure 3B-E). After chol-
esterol treatment, large vesicles surrounding early endo-
somes were more frequent (Figure 3C and D). The
surface of individual EEA1-labelled profiles was quanti-
fied (Figure 3F). We observed that the surface of early
endosomes in control cells (98635 ± 3457 nm2, 244
endosomes) was significantly smaller than it was in
cholesterol-loaded neurons (122495 ± 4941 nm2, 284
endosomes) (24% increase, p < 0.0001, unpaired t test
with Welch’s correction). After cholesterol loading,
17% of EEA1-positive endosomes formed aggregates
(Figure 3E), whereas only 4% formed aggregates under
control conditions. EEA1-positive endosomes thus ap-
peared more prone to aggregation after membrane
cholesterol increase. These results highlight that, aftermembrane cholesterol loading, endosomes were not
only larger in surface but also formed more aggregates.
We investigated the number of ILVs per endosome
(Figure 3G). In control conditions, EEA1 positive endo-
somes exhibited 4.3 ± 0.3 ILVs per endosome (1060 ILVs,
244 endosomes) whereas after cholesterol treatment, the
ILVs number was significantly increased to 7.0 ± 0.5 ILVs
per endosome (1978 ILVs, 284 endosomes) (p < 0.0001,
unpaired t test with Welch’s correction). Thus, there
were more ILVs in EEA1-positive endosomes after chol-
esterol treatment. Nevertheless, when we normalized the
number of ILVs per endosome with the endosomal surface
for each endosome, we found no significant difference be-
tween ratios in control conditions or after membrane
cholesterol loading (Figure 3H, 244 control endosomes,
284 endosomes after cholesterol, p = 0.0535, unpaired
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may be linked to the endosome surface enlargement.
We thus showed that cholesterol increase at the neur-
onal membrane led to larger endosomal vesicles that were
more prone to aggregation.
High membrane cholesterol inhibited vesicular trafficking
in neuritic processes
Defective axonal vesicular transport is associated with
early stages of sporadic AD [23,24,32]. We thus addressed
the effect of membrane cholesterol loading on APP
vesicular transport in neuronal processes by perform-
ing live imaging experiments on neurons expressing
APP-mCherry. Typical APP-mCherry expression in
processes is presented in Figure 4 under control condition
(A), after addition of neurobasal medium alone (B) or of
MβCD-cholesterol dissolved in neurobasal medium (C).
As previously reported, APP exhibited both anterograde
(away from the soma) and retrograde transport (towards
the soma) [33]. The mean speed of APP vesicles was
2.2 ± 0.03 μm/sec (n = 726 measures from 46 neurons
in three independent cultures) for anterograde trans-
port and 1.8 ± 0.03 μm/sec (n = 595 measures from 46
neurons in three independent cultures) for retrogradeFigure 4 Membrane cholesterol loading inhibits APP vesicular traffick
expression in neuritic processes and kymographs obtained from live-imagin
medium alone addition (B and E) or after MβCD-cholesterol dissolved in neu
vesicles (ns stands for p > 0.05 in unpaired Student’s t test, n = 52 control and
Welch’s correction, n = 52 control and 30 cholesterol-treated neurons). (H) Me
stands for p > 0.05 in one-way ANOVA with Tukey’s post-test (n = 595 measur
cholesterol-treated neurons). For anterograde transport, ns stands for p > 0.05
measures for control, 365 measures for neurobasal-treated and 241 measurestransport in control conditions. A wide range of values
have been reported for APP velocities. Discrepancies
could be due to different APP constructs, culture condi-
tions, maturity of the neurons and also to the methods of
acquisition and analysis of the data. The mean velocity we
obtained for anterograde transport (2.2 μm/sec) fits in the
reported range (0.8 to 4.5 μm/sec) [33-38].
The mobility of APP-containing vesicles was deter-
mined at time 0 and then kinetically followed over
half an hour after neurobasal medium alone or
MBCD-cholesterol dissolved in neurobasal medium
addition. For each time point, a kymograph was
drawn (Figure 4D-F) and the percentage of immobile
vesicles (i.e., speed < 0.5 μm/sec in either direction)
was extracted (Figure 4G). At time zero, 50 ± 2% of
APP vesicles were stationary (n = 52 neurons observed
in 13 independent experiments from 4 different cul-
tures). Adding fresh neurobasal medium did not modify
the mobility of APP vesicles (51 ± 2%, n = 24 neurons in
6 independent kinetic experiments from three different
cultures; p = 0.802, unpaired Student’s t test). However,
loading plasma membrane with cholesterol significantly
increased the percentage of stationary vesicles (63 ± 4%,
n = 30 neurons in 6 independent kinetic experimentsing in neuronal processes. (A-F) Representative APP-mCherry
g experiments in control condition (A and D), after neurobasal
robasal medium treatment (C and F). (G) Proportion of stationary APP
24 neurobasal-treated neurons and ** for p < 0.01 in unpaired t test with
an velocity of the remaining moving vesicles. For retrograde transport, ns
es for control, 218 measures for neurobasal-treated and 268 measures for
and *** for p < 0.001 in one-way ANOVA with Tukey’s post-test (n = 726
for cholesterol-treated neurons).
Figure 5 Membrane cholesterol increase in cultured cortical
neurons leads to lower Aβ38 (38% less, p = 0.0017, unpaired
Student’s t-test, n = 12 control and 10 cholesterol assays in
three independent experiments) and higher Aβ42 secretion
(24% more, p = 0.0334, unpaired Student’s t-test, n = 11 control
and 10 cholesterol assays in three independent experiments),
while Aβ40 stayed unchanged (less than 2% change, p = 0.6322,
unpaired Student’s t-test, n = 16 control and 15 cholesterol assays
in four independent experiments), as assessed by MesoScale
Discovery dosage. ns stands for non-significant (p > 0.05), *for
p < 0.05 and **for p < 0.01 in unpaired Student’s t-test.
Marquer et al. Molecular Neurodegeneration 2014, 9:60 Page 8 of 13
http://www.molecularneurodegeneration.com/content/9/1/60from three different cultures; p = 0.008, unpaired t test
with Welch’s correction).
We analyzed the velocity of the remaining moving
vesicles. The mean speed of retrograde transport of APP
vesicles was 1.8 ± 0.05 μm/sec (n = 218 measures from
21 neurons in three independent cultures) after neuro-
basal medium addition and 1.7 ± 0.05 μm/sec (n = 268
measures from 29 neurons in three independent cultures)
after membrane loading with cholesterol (Figure 4H).
This retrograde velocity was not modified by neuroba-
sal medium nor by cholesterol (p = 0.1658, one-way
ANOVA). The mean speed of anterograde transport of
APP vesicles was 2.3 ± 0.05 μm/sec (n = 365 measures
from 21 neurons in three independent cultures) after
neurobasal medium addition and 1.9 ± 0.06 μm/sec
(n = 241 measures from 29 neurons in three independent
cultures) after membrane loading with cholesterol
(Figure 4H). Mean anterograde transport speeds were
significantly different (p < 0.0001, one-way ANOVA).
Performing Tukey’s post-test revealed that there was
no significant difference between mean anterograde
speeds of APP vesicles at time 0 or after neurobasal
addition (p > 0.05) while anterograde speeds after mem-
brane loading with cholesterol were significantly decreased
from anterograde speeds at time 0 (p < 0.001) or after neu-
robasal addition (p < 0.001).
We found that cholesterol increase led to decreased
mobility of APP-containing vesicles while the speed of
the remaining vesicles in movement was not affected in
the retrograde direction but significantly decreased in
the anterograde direction.
Cholesterol has been suggested to reduce the mobility
of vesicles transported along microtubules [39-41]
though this effect was not described previously in neu-
rons, to our knowledge. In non-neuronal cell types, chol-
esterol levels can be sensed by oxysterol-binding protein
ORP1L, thus impacting on the rab7/RILP/p150Glued
complex and on the dynein/dynactin complex which is es-
sential for retrograde transport [40]. Dynein dysfunction
actually disrupts both retrograde and anterograde trans-
port [42], through an increase in rab3 GTPase [42]. Inter-
estingly, rab3 is essential for APP vesicular transport in
neuronal processes [43]. We observed that expression of
Osbpl1a, which encodes ORP1L, was up-regulated after
membrane cholesterol loading (Table 2).
High membrane cholesterol increased endogenous Aβ 42
secretion in cultured neurons
We previously showed in cultured cell lines that increase
of cholesterol at the plasma membrane can trigger APP
endocytosis and Aβ secretion [13]. Here we quantified
the levels of endogenously secreted Aβ peptides after
loading the plasma membrane of embryonic rat cortical
neurons with 30% more cholesterol. Concentrations ofAβ peptides of 38, 40 and 42 amino acids were assessed
using Mesoscale Discovery multiplex assay. Conditioned
media was collected after 24 hours in order to reach the
sensitivity threshold for less-abundant isoforms quanti-
fication. Overall, the amount of Aβ peptides was com-
parable between control and cholesterol-loaded neurons
(p = 0.8397, t test). Nevertheless, we observed discrep-
ancies when we analyzed each isoform separately. While
the levels of Aβ40 remained unchanged after cholesterol
treatment (less than 2% change), Aβ38 exhibited a signifi-
cant decrease (38% less) and Aβ42 a significant increase
(24% more) (Figure 5).
Increased membrane cholesterol was thus associated
with a higher production of endogenous neuronal Aβ42
peptides and with an elevated Aβ42 to Aβ40 ratio. In-
crease of Aβ42 secretion could be highly detrimental to
neurons as this isoform is the most prone to form toxic
oligomeric species [44]. We previously showed that, in
HEK293 cells over-expressing the Swedish mutant of
APP, both Aβ40 and Aβ42 peptides were up-regulated
after cholesterol augmentation [13], thus highlighting
the importance of both cell type and APP isoform when
studying APP processing.
It was recently reported that Aβ38 results from γ-
secretase processing of either Aβ42 or Aβ43 [45].
Interestingly, APP lysine 624, which was described as
essential in regulating the final Aβ peptide length re-
leased by γ-secretase [46], is located in the APP/
cholesterol interaction site [14]. Excess of cholesterol
binding to APP may thus alter γ-secretase processing
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creased Aβ42 and decreased Aβ38 peptides levels we
observed.
Conclusion
Membrane cholesterol has been shown to be increased
in post-mortem brains from sporadic AD patients and to
correlate with disease progression [5]. We suggested that
an increase of membrane cholesterol could be an early
event in the etiology of sporadic AD. To test this hypoth-
esis, we acutely increased levels of plasma membrane
cholesterol of neurons in culture. This treatment induced
a 30% increase mimicking what was observed in AD
brains [5-7]. We showed that this transient membrane
cholesterol increase triggered Aβ42 over-production,
endosomal enlargement, vesicular transport deficits in
neuronal processes and gene expression modulation as
in early sporadic AD. This model of neuronal primary
cultures treated with cholesterol could thus be relevant
to study early events in sporadic AD.
Using both confocal and electron microscopy, we inves-
tigated the number, surface, ILVs number and aggregation
status of EEA1-positive early endosomes after cholesterol
treatment. This is to our knowledge the first time that
neuronal endosomal enlargement is investigated in such
quantitative detail. After membrane cholesterol loading,
the number of early endosomes per neuron was not al-
tered but we found that their size was enlarged and that
more ILVs were associated with each endosome. EEA1-
positive endosomes in neurons loaded with cholesterol
were also more prone to form aggregates. As cholesterol
is highly concentrated in myelin [47], excess cholesterol in
sporadic AD brains could result from demyelination
linked to age, the major risk factor for AD. Indeed, genes
involved in cholesterol synthesis were down-regulated in a
mouse demyelination model [48], as we also observed in
our model of external cholesterol addition. It still remains
unclear whether myelin degradation could be the origin of
higher membrane cholesterol that is described as a marker
of disease progression [5]. The topography of cholesterol
embedded in the membrane seems to be crucial as was
highlighted in an AD mouse model where the cholesterol
content of lipid rafts, but not the total brain cholesterol
levels, was correlated with amyloid load and behavioral
deficits [49]. The link between tau pathology, the other
hallmark of AD, and cholesterol is still unclear. Here we
show that membrane cholesterol increase leads to overex-
pression of the kinase Fyn gene using microarray gene
profiling and RT-QPCR (Table 2). Tau is known to inter-
act with Fyn and to facilitate Fyn targeting to dendrites.
Once in the postsynaptic compartment, Fyn phosphory-
lates the N-methyl-D-aspartate (NMDA) receptor subunit
2B (NR2B) and stabilizes its interaction with postsynaptic
density protein 95 (PSD95) (reviewed in [50]. The NR2B/PSD95 interaction is essential in mediating Aβ-induced
excitotoxicity [51]. Fyn could thus be an interesting link
between cholesterol, Aβ and tau.
In conclusion we have shown that an increase in
neuronal membrane cholesterol triggers APP process-
ing, endosomal trafficking and axonal transport abnor-
malities and induces gene expression changes that are
reminiscent of early stages of sporadic AD. We propose
that an increase in membrane cholesterol linked with age
is one of the initial events that could trigger sporadic AD.
Thus specifically decreasing neuronal membrane choles-
terol could be an interesting therapeutic strategy, which
has already been successfully applied in mouse models of
AD [49,52]. It was recently shown that stimulating choles-
terol synthesis in mouse models overexpressing amyloid
induces tau phosphorylation and neurofibrillary tangles
formation, suggesting that cholesterol increase might trig-
ger amyloid and tau pathologies [53]. Loading the mem-
brane of cultured neurons with cholesterol could thus be
used as a new cellular model to study early AD changes,
identify new targets and screen new molecules.
Methods
Plasmids and reagents
The APP751 plasmid was a kind gift from Dr. Frederic
Checler (IPMC, Valbonne, France). The APP-mCherry
plasmid was generated by introducing the APP751 se-
quence in the pmCherry-N1 vector (Clontech, Mountain
View, CA, USA) at the XmaI/AgeI restriction site. MβCD-
cholesterol complex, saponin, bovine serum albumin
(BSA), sucrose and poly-L-lysine were purchased from
Sigma-Aldrich (Saint-Louis, MO, USA). The antibody
directed against EEA1 (Early Endosome Antigen 1) was
from Cell Signaling Technology (Danvers, MA, USA).
Goat anti rabbit IgG coupled to Alexa568 was from Life
Technologies (Carlsbad, CA, USA).
Primary neuronal cultures
Primary hippocampal and cortical cultures were pre-
pared from E16-18 OFA Sprague Dawley rat embryos
(Charles River, Wilmington, MA, USA). Hippocampi
and cortices were dissected in cold PBS supplemented
with 45% glucose (Sigma-Aldrich, Saint-Louis, MO,
USA). Digestion was performed in a 0,05% solution of
Trypsin-EDTA (Life Technologies, Carlsbad, CA, USA)
for 25 min at 37°C. Tissues were then mechanically
dissociated in Dulbecco’s Modified Eagle Medium-1
(Life Technologies, Carlsbad, CA, USA) supplemented
with 5% fetal bovine serum (Life Technologies, Carlsbad,
CA, USA) and centrifuged for 10 min at 800 rpm. Neu-
rons were resuspended in neurobasal medium supple-
mented with 2% B27, 2 mM glutamax, 1% penicillin/
streptomycin (all from Life Technologies, Carlsbad, CA,
USA) and counted.
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Unless otherwise mentioned, neurons were washed twice
with neurobasal medium, treated with 1.4 mM MβCD-
cholesterol dissolved in neurobasal medium and then
washed three times with neurobasal medium. Treatment
of neurons with 1.4 mM MβCD-cholesterol for 30 min re-
sulted in an increase of 28.4 ± 6.0% of cellular cholesterol
levels, as assessed previously by filipin staining [12].
Aβ 38, 40 and 42 measurements
Cortical neurons were plated on 12-well plates coated
with poly-L-lysine (1 mg/ml) at a density of 2 million neu-
rons per well and maintained at 37°C in a humidified 5%
CO2 atmosphere. After cholesterol treatment at DIV4-6,
neurons were placed in fresh neurobasal medium sup-
plemented with 2% B27, 2 mM glutamax for 24 h. Su-
pernatants were collected on ice in polypropylene tubes
(Corning, Corning, NY, USA) containing a protease inhibi-
tor cocktail (Roche, Penzberg, Germany) and were then
stored at −80°C. Concentrations of the Aβ38, Aβ40 and
Aβ42 species of β-amyloid peptide were measured by
multiplex Electro-Chemiluminescence Immuno-Assay
(ECLIA). Assays were performed according to the man-
ufacturer's instructions. Briefly, samples were analyzed
using Meso Scale Discovery (MSD) SECTOR™ Imager
2400 (Meso Scale Discovery, Gaithersburg, MD, USA),
with the Rodent Aβ triplex kit (also from MSD); carbon
96-well plates contained in each well four capture spots,
one of which was blocked with BSA (as standard curve
control), and the three others coated with isoform specific
anti-Aβ antibodies specific for Aβ38, Aβ40, Aβ42, respect-
ively. 100 μl of blocking buffer solution were added to all
wells to avoid non-specific binding. The plates were then
sealed, wrapped in tin foil, and incubated at room
temperature on a plate shaker (600 rpm) for 1 h. Wells
were then washed three times with washing buffer, and
25 μl of the standards (Aβ38, Aβ40, Aβ42) and samples
were then added to the wells, followed by an Aβ-detecting
antibody at 1 μg/ml (MSD) labelled with a Ruthenium (II)
trisbipyridine N-hydroxysuccinimide ester; this detection
antibody was 4G8 (which recognizes the epitope Aβ18-22
of the human and rodent peptide). Plates were then aspi-
rated and washed 3 times. MSD read buffer (containing
TPA) was added to wells before reading on the Sector
Imager. A small electric current passed through a micro-
electrode present in each well producing a redox reaction
of the Ru2+ cation, emitting 620 nm red light. The concen-
tration of each Aβ isoform was calculated for each sample,
using dose–response curves, the blank being cell-less cul-
ture medium.
EEA1 Immunocytochemistry and confocal microscopy
Cells cultured on poly-L-lysine-coated coverslips were
fixed at DIV4-5 or DIV14 using a solution of 4%paraformaldehyde and 4% sucrose in Phosphate Buffered
Saline (PBS) for 20 min at room temperature. Cells were
then washed twice in PBS and incubated with NH4Cl
(50 mM in PBS) for 10 min. Cells were washed twice again
in PBS. They were permeabilized with solution A (0.3%
BSA and 0.05% saponin in PBS) for 45 min at 37°C and
were then incubated at room temperature for 1 h with
primary antibody against EEA1 diluted (1/1000) in so-
lution A. Cells were subsequently incubated at room
temperature for 1 h with goat anti rabbit secondary
antibody conjugated to Alexa568 diluted in solution A
(1/1000). Coverslips were mounted in Fluoromount-G
(SouthernBiotech, Birmingham, AL, USA). Z-stacks of
neurons were acquired on a Fluoview FV1000 confocal
microscope (Olympus, Tokyo, Japan) with the 543 nm
line of a He/Ne laser. Fluorescence was collected with
a 60× plan apochromat immersion oil objective (NA
1.35) between 560–660 nm. The mean endosome size
and the mean endosome number per neuron were ana-
lyzed with ICY software [54]. Between 13 and 17 neurons
were analyzed for each experiment. Each experiment was
independently repeated 3 times.
Pre-embedding immunoperoxidase electron microscopy
Neurons grown on Thermanox coverslips were processed
through all stages in situ. They were fixed with 4% PFA,
0.1% glutaraldehyde diluted in PBS, rinsed with PBS, cryo-
protected in 30% glycerol, 30% ethylene glycol in PBS and
stored at −20°. After PBS rinses, they were blocked in 5%
normal goat serum and incubated at room temperature
overnight with the antibody against EEA1 diluted 1/1000
in PBS. A biotinylated anti-rabbit IgG (Vector, CA, USA)
was applied as secondary antibody (1/200 in PBS, 2 h),
followed by ABC peroxidase complex (Vectastain Elite,
Vector, CA, USA) with 0.05% diaminobenzidine as
chromogen. After 2% OsO4 post-fixation and dehydra-
tion in graded acetone including a 1% uranyl staining
step in 70% acetone, coverslips were embedded in Epon
resin. Thin (70 nm) sections were lightly stained with
lead citrate and observed under a Philips CM120 elec-
tron microscope (Philips, Eindhoven, The Netherlands)
operated at 80 kV. Images were recorded with a Morada
digital camera (Olympus Soft Imaging Solutions GmbH,
Münster, Germany). The measurements were performed
with the associated iTEM software.
Videomicroscopy
Cortical neurons in suspension (5 million) were electro-
porated with Amaxa Nucleofector kit for rat neurons
(Lonza, Basel, Switzerland) according to the supplier’s
manual. Electroporated neurons were plated on 8-well
Labteks coated with poly-L-lysine (1 mg/ml). After
3 hours, medium was replaced with fresh neurobasal
supplemented with 2% B27, 2 mM glutamax and 1%
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37°C in a humidified 5% CO2 atmosphere. Sixteen hours
before performing video experiments, 10 μM forskolin
(Sigma-Aldrich, Saint-Louis, MO, USA) and 100 μM
IBMX (Sigma-Aldrich, Saint-Louis, MO, USA) were
added to the medium. Videomicroscopy experiments
were performed at DIV3-5. APP-containing vesicles were
imaged in control condition and then for 35 minutes after
adding neurobasal medium alone or MβCD-cholesterol
dissolved in neurobasal medium (1.4 mM final concentra-
tion). Live videomicroscopy was carried out using an
Axiovert 200 microscope (Zeiss, Jena, Germany) with a PL
APO oil × 63 objective of numerical aperture of 1.40.
Records were made with a Photometrics Evolve 512
camera (Roper Scientific, Trenton, NJ, USA) controlled
by Metamorph software (Molecular Devices, Sunnyvale,
CA, USA). Stacks were acquired at 37°C. Images were
collected in stream set at 1 × 1 binning with an exposure
time of 200 ms. Kymographs were generated and analyzed
with a homemade ImageJ plugin, KymoToolbox, available
upon request (contact: Fabrice.Cordelieres@curie.fr). Seg-
mental velocities were defined as the speed a particle
travels in one direction without a pause or a reversal in
the direction of movement.
cRNA probe preparation and hybridization
Hippocampal rat neurons (1.1 to 1.4 million) were treated
with MβCD-cholesterol at DIV 4–6 and left in neurobasal
medium for 4 h and 30 min. They were then harvested
and centrifuged. The dry pellet was kept at −80°C. Total
RNAs were extracted using Nucleospin RNA II kit
(Macherey Nagel, Duren, Germany) in accordance with
the manufacturer’s protocol. The quality and quantity of
each RNA preparation were assessed on an Agilent 2100
Bioanalyzer with RNA 6000 NanoChips (Agilent Tech-
nologies, Santa Clara, CA, USA). One hundred ng of each
RNA were amplified and labeled with Cy3 using the Low
Imput Quick Amp labeling kit (Agilent Technologies,
Santa Clara, CA, USA) according to the manufacturer’s
instructions. After purification and quantification on a
Nanodrop (ThermoFisher Scientific, Waltham, MA, USA),
2 μg of each Cy3-cRNA were hybridized overnight on
Whole Rat Genome Microarray 4×44 K (Agilent Tech-
nologies, Santa Clara, CA, USA) according to the manu-
facturer’s instructions.
Microarray data analysis
Microarray data were acquired on a ScanArray GX (Per-
kin Elmer, Waltham, MA, USA) with a resolution of
5 μm and analyzed with Mapix 5.0.0 software (Innopsys,
Carbonne, France). For each sample, raw data consisted
of the Median Feature Intensity – Median Background
Feature (F-B) at 532 nm wavelength. These raw data
were log2-transformed and quantile-normalized underthe R freeware (www.r-project.org). The statistical ana-
lysis was performed on these normalized data under the
R freeware. All the microarray data have been deposited
on the GEO database under the accession number
GSE46221.
Gene Ontology (GO) category enrichment analysis was
realized using the web-based GOrilla application [55,56]
(http://cbl-gorilla.cs.technion.ac.il/). Statistical significance
was set to a p value <0.001.
Hierarchical Classification was performed using MeV
4.7.4 software (http://www.tm4.org/).
Quantitative PCR (qPCR)
Three hundred nanograms of each RNA were individu-
ally reverse-transcribed into cDNAs for 2 hours at 42°C
using the Maxima First strand synthesis kit (Fermentas
GmbH, Germany) according to the manufacturer’s in-
structions. qPCR assays were performed in a Lightcycler®
480 System (Roche), in the presence of 200nM of each
primer, 100nM of specific hydrolysis probe (designed with
Universal Probe Library, Roche Applied Science) and 1X
Solaris qPCR Master mix (Fermentas GmbH, Germany).
Gene expression was normalized using HPRT and pPib as
reference genes.
Statistical analysis
Most statistical calculations were performed using Graph-
Pad Prism software (version 5.0). All the data are given as
mean ± SEM.
κ-means analysis of fluorescently-labelled endosome
size was performed using the statistic analysis toolbox of
Matlab software (version R2012a). Endosome sizes under
control conditions were distributed into three size clas-
ses defined by the κ-means algorithm using the squared
Euclidian distances. This iterative partitioning minimizes
the sum, over all clusters, of the within-cluster sums of
point-to-cluster-centroid distances. Each endosome was
assigned an index corresponding to one of the three clus-
ters defined in the iterative loop (small, medium, large).
The partition of endosome sizes after cholesterol treat-
ment in these three classes was then determined.
The χ2 comparison test of the two distributions of
endosome size was made with Matlab sofware (version








with i (1 to 3) as the size categories (small, medium,
large) and j (1 to 2) as the two groups (control and
treated). n is the number of neurons falling into each
class. The degree of freedom was (ni-1) × (nj-1) = 2.
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